EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aprogen KIC Inc (007460) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Aprogen KIC Inc KRW 1,131, price KRW 2,010, upside -43.7%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Industrials · KR · ISIN KR7007460009

AK Thin data Sep 24, 2026

Aprogen KIC Inc

007460 · KO

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,131 KRW · Strongly overvalued (−44%)
!Quality 23/100
!Weak Growth (revenue 5y −1.5 %/yr)
!Loss-making · -57.5% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (1/8)
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
Watch Aprogen KIC Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

115,425 KRW 1,962 KRW Fair Value 1,131 KRW Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1,962 KRW – 115,425 KRW · fair‑value band 844.12 KRW – 1,688 KRW · the 2,010 KRW price screens above the 1,131 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Aprogen KIC in your weekly email

Every Wednesday you see whether Aprogen KIC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs.

Show more

Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 2000 and is based in Seongnam-si, South Korea.

Stock analysis

Aprogen KIC Inc (007460) currently trades at 2,010 KRW, while our model-based Fair Value estimate is 1,131 KRW, implying the stock looks roughly 77.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: 844.12 KRW (bear) to 1,688 KRW (bull), the price of 2,010 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Industrials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Aprogen KIC Inc reported revenue of 118B KRW in FY2025 versus 141B KRW in FY2021, a compound −4.4%/yr. Reported net income was −70.2B KRW in FY2025.

Key figures

Market cap 48.6B KRW (≈ $35.7M) · P/S ratio 0.38 · Net margin −59.5% · Return on equity −32.7% · Return on assets (EBIT) −12.4% · Operating margin −56.8% · Revenue (TTM) 128B KRW · Revenue growth (YoY) +35.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 85% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at 16% fair-value upside, at −44%, 007460 screens richer than that median.

Fair Value models

Bear 844.12 KRW Fair Value 1,131 KRW Bull 1,688 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3,762 KRW 5,042 KRW 7,525 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 3,762 KRW 5,042 KRW 7,525 KRW 54

Open the full fair value analysis →

Notify me when 007460 reaches fair value

Put 007460 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 22 · Market factors (momentum, volatility) 16

Profitability 2
Margins and returns on capital today
Quality Growth 31
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 21
Balance sheet, leverage, solvency risk
Investment 56
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 50
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−21.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic)
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.3% (2019) → −81.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

007460 screens 78% overvalued. Compare with 3M Company →

Compare Aprogen KIC Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Conglomerates · 378 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −44% · Below median
Profitability
Return on assets −9% · Bottom 25%
Net margin (TTM) −57% · Bottom 25%
Operating margin (TTM) −57% · Bottom 25%
Growth and dividend
Revenue growth 36% · Top 25%
Balance sheet
Debt / equity 0.25× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 16
PAST (return on equity)0 · sector 19
HEALTH (low debt)87 · sector 89
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Conglomerates stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
3M Company MMM $170.30 $71.86 −58%
Honeywell International Inc HON $212.57 $243.57 +15%
CITIC Limited 0267 HK$13.08 HK$26.16 +100%
Poste Italiane S.p.A PST €25.71 €9.10 −65%
Swire Pacific Limited 0019 HK$102.80 HK$28.34 −72%
CK Hutchison Holdings 0001 HK$67.60 HK$135.20 +100%
SK Inc 034730 611,000 KRW 351,594 KRW −42%
Jardine Matheson Holdings J36 $57.30 $79.11 +38%
Kingboard Holdings 0148 HK$55.55 HK$85.25 +53%
SGH Limited SGH A$36.69 A$42.47 +16%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aprogen KIC Inc · Fair Value
1,131 KRW −78%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aprogen KIC Inc Fair Value". https://www.fairvalue-calculator.com/stock/007460

Frequently asked questions

Is Aprogen KIC Inc (007460) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,131 KRW versus a price of 2,010 KRW, about −44% upside (overvalued).
What is the fair value of 007460?
Our model-based fair value for Aprogen KIC Inc is 1,131 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,010 KRW.
What is the quality score of 007460?
Aprogen KIC Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aprogen KIC Inc (007460)?
Our model-based price target is the fair value of 1,131 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 844.12 KRW, optimistic scenario 1,688 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Aprogen KIC Inc stock forecast for 2026?
Our models put fair value at 1,131 KRW, about −44% upside versus a price of 2,010 KRW (overvalued). Cautious scenario 844.12 KRW, optimistic scenario 1,688 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aprogen KIC Inc (007460)?
Aprogen KIC Inc reported trailing-twelve-month revenue of about 128B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Aprogen KIC Inc (007460)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aprogen KIC Inc it is 1,131 KRW per share (as of Sep 24, 2026), against a price of 2,010 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Aprogen KIC Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 007460 trades above its calculated fair value: price 2,010 KRW, fair value 1,131 KRW, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 007460?
No. The price is what the market pays today (2,010 KRW); the fair value is what the company's own numbers justify (1,131 KRW). For Aprogen KIC Inc the two are 878.88 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aprogen KIC Inc worth?
The market values Aprogen KIC Inc at about 48.6B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,010 KRW; our models calculate a fair value of 1,131 KRW per share.
What do the bullish and bearish scenarios say about 007460?
Our models span a range for Aprogen KIC Inc: cautious scenario 844.12 KRW, base 1,131 KRW, optimistic 1,688 KRW per share (as of Sep 24, 2026, price 2,010 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aprogen KIC Inc (007460)?
Balance-sheet figures for Aprogen KIC Inc (as of Sep 24, 2026): return on equity −32.7%, debt of 0.25 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 007460 from its 52-week high?
Aprogen KIC Inc trades at 2,010 KRW, about 85% below its 52-week high of 13,650 KRW and 2% above the low of 1,962 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,131 KRW is for.
Which stocks are comparable to Aprogen KIC Inc?
From the same area (Industrials) we also value 3M Company, Honeywell International Inc, CITIC Limited, Poste Italiane S.p.A, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aprogen KIC Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 2,010 KRW, calculated fair value 1,131 KRW (−44%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 007460 calculated?
We run Aprogen KIC Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,131 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Aprogen KIC Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aprogen KIC Inc (007460)?
The closing price on Sep 23, 2026 was 2,010 KRW. Our model-based fair value is 1,131 KRW, about −44% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aprogen KIC Inc right now?
The price sits above even our optimistic bull case (1,688 KRW). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (844.12 KRW to 1,688 KRW) leaves room in how you read the outcome.

Key figures of Aprogen KIC Inc

How large is the market capitalisation of Aprogen KIC Inc (007460)?
The market capitalisation of Aprogen KIC Inc is 48.6B KRW (≈ $35.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aprogen KIC Inc (007460)?
The price-to-sales ratio of Aprogen KIC Inc is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Aprogen KIC Inc (007460)?
The net margin of Aprogen KIC Inc is −59.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aprogen KIC Inc (007460)?
The return on equity (ROE) of Aprogen KIC Inc is −32.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aprogen KIC Inc (007460)?
On an EBIT basis the return on assets of Aprogen KIC Inc is −12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aprogen KIC Inc (007460)?
The operating margin of Aprogen KIC Inc is −56.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aprogen KIC Inc (007460)?
Revenue at Aprogen KIC Inc is growing +35.8% versus a year earlier (3y avg +14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aprogen KIC Inc (007460)?
Earnings per share at Aprogen KIC Inc are growing −92.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aprogen KIC Inc (007460) generate?
The free cash flow of Aprogen KIC Inc is −64.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Aprogen KIC Inc (007460) carry?
The net debt of Aprogen KIC Inc is 141B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aprogen KIC Inc in the live analysis

One click puts Aprogen KIC Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.